From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Vivus (NASDAQVVUS) is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials.[1] The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra.[2] Stendra is the first and only oral ED treatment approved to be taken approximately 15 minutes before sexual activity.[3]

A documentary movie "Orgasm Inc." was made at Vivus in 2009 to document the process of creating a treatment for Female sexual arousal disorder (FSD).

Vivus also developed an obesity drug, Qnexa (now called Qsymia), a combination of phentermine and topiramate, two existing weight-loss drugs.[4] On July 17, 2012, The U.S. Food and Drug Administration approved Qsymia (phentermine and topiramate extended-release), made by Vivus, as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug was approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).[5][6]

In 2016, the company was ranked #23 on the Deloitte Fast 500 North America list.[7]


  1. ^ Phase 3 Data on VIVUS' Avanafil for Erectile Dysfunction to be Featured at the AUA 2010 Annual Meeting, "[1]"
  2. ^ "Most Popular in Your Life". USA Today.
  3. ^ "VIVUS and Auxilium Announce Stendra Label Expansion". Zacks Investment Research.
  4. ^ Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP), "[2]"
  5. ^ Hellmich, Nancy (17 July 2012). "New diet drug helps patients lose about 10% of weight". USA Today. Retrieved 17 July 2012.
  6. ^ "Medications Target Long-Term Weight Control". Retrieved 17 July 2012.
  7. ^ "2016 Winners by rank" (PDF). Deloitte. Retrieved 14 October 2017.

External links[edit]